Related Experiment Videos
[Piracetam in severe cranio-cerebral injuries]
I Gościński1, S Sliwonik, T Sondej
1Kliniki Neurotraumatologii Instytutu Neurologii Collegium Medicum UJ.
Neurologia I Neurochirurgia Polska
|August 27, 1999
Summary
Piracetam administration improved outcomes for patients with cranio-cerebral injuries when given at higher doses (24-30 mg/day) with proper oxygen and glucose management. Early and continued piracetam therapy is recommended for head injury patients.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Cranio-cerebral injuries pose significant risks to neurological function.
- Piracetam is a nootropic agent with potential neuroprotective and cerebrovascular effects.
Purpose of the Study:
- To evaluate the efficacy of piracetam in patients with cranio-cerebral injuries.
- To determine optimal dosing and conditions for piracetam administration in this patient population.
Main Methods:
- Analysis of 100 patients treated immediately after cranio-cerebral injury.
- Administration of piracetam via intravenous infusion (GCS 3-8) or orally (GCS >9).
- Dosing varied (6-10 mg/day vs. 24-30 mg/day) with controlled oxygen and glucose levels.
Main Results:
- Lower doses (6-10 mg/day) showed no significant positive effect.
- Higher doses (24-30 mg/day) demonstrated significant positive therapeutic effects.
- Optimal results were achieved when maintaining adequate partial oxygen pressure and blood glucose levels.
Conclusions:
- Piracetam is beneficial for cranio-cerebral injury patients, particularly at higher doses (24-30 mg/day).
- Therapeutic success is contingent on supportive measures like oxygen therapy and glucose control.
- Intravenous piracetam is recommended immediately post-injury, followed by oral therapy upon discharge.